Sign In
Buy IOVA
$4.38
+0.590 (+15.57%)
At Close: Jun 04, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
02:15pm, Wednesday, 14'th May 2025
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors
Ongoing Investigation: Iovance Biotherapeutics, Inc. (IOVA) May Have Misled Shareholders - Levi & Korsinsky Investigates
10:15am, Wednesday, 14'th May 2025
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IO
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IO
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (�
Lost Money on Lovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
02:45pm, Tuesday, 13'th May 2025
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IO
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IO
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company
Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman
09:00am, Tuesday, 13'th May 2025
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the
Kirby McInerney LLP Announces Investigation of Claims Against Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
08:00pm, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Iovance Biotherapeutics,
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the
Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity
01:28am, Monday, 12'th May 2025
Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manuf
3 Monster Stocks in the Making
11:15am, Sunday, 11'th May 2025
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
